US Stock MarketDetailed Quotes
CGTX Cognition Therapeutics
- 0.440
- 0.000-0.05%
Close Nov 21 16:00 ET
18.27MMarket Cap-458P/E (TTM)
0.446High0.428Low508.24KVolume0.440Open0.440Pre Close223.19KTurnover1.44%Turnover RatioLossP/E (Static)41.55MShares2.95052wk High1.26P/B15.55MFloat Cap0.34052wk Low--Dividend TTM35.35MShs Float13.800Historical High--Div YieldTTM3.98%Amplitude0.340Historical Low0.439Avg Price1Lot Size
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data
Cognition Therapeutics Stock Forum
Cognition Therapeutics Presents Poster of Participant Demographics from Phase 2 Dementia with Lewy Bodies Study at CTAD
Cognition Therapeutics (NASDAQ: CGTX) presented baseline characteristics of participants in their Phase 2 'SHIMMER' study for dementia with Lewy bodies (DLB) at the CTAD conference. The study includes 130 participants with these key characteristics: mean age of 72.8 years, 81.5% male, 91.5% white, with mild-to-moderate cognitive impairment....
Analyses from Cognition's Positive Phase 2 'SHINE' Study of CT1812 in Mild-to-Moderate Alzheimer's Disease will be Presented in a Podium Presentation at CTAD
Presenting prespecified analysis of cognitive impact on plasma p-Tau 217 subgroups in ‘SHINE'
Poster Presentation details baseline characteristics from the signal-finding ‘SHIMMER' trial in DLB
PURCHASE, N.Y., Oct. 23, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the Company or Cognitio...
Mild-to-moderate DLB
Phase 2 COG1201 • SHIMMER
Topline data 2H-2024
📊⚡️📊
No comment yet